{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.1","upperLimit":"52.1","value":"2.53"},{"groupId":"OG001","lowerLimit":"1.2","upperLimit":"22.2","value":"1.58"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"90"}],"units":"Participants"}],"description":"TTR was defined as the time from randomization to the date of the first confirmed documented response (CR or PR), as assessed by the BICR. TTR was evaluated for responders (confirmed CR or PR) only.","dispersionType":"Full Range","groups":[{"description":"Nivolumab + Ipilimumab + Chemotherapy","id":"OG000","title":"Treatment A"},{"description":"Chemotherapy only","id":"OG001","title":"Treatment B"}],"paramType":"MEDIAN","populationDescription":"All Confirmed Responders, Global Population","reportingStatus":"POSTED","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)","title":"Time to Response (TTR)","type":"SECONDARY","unitOfMeasure":"Months"}